The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers.
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunomet; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Glenn J. Hanna
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Bicara Therapeutics; Bio-Rad; Bristol-Myers Squibb; Exicure; Kura Oncology; Maverick Therapeutics; Merck; Naveris; Prelude Therapeutics; Regeneron; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); EMD Serono (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Maverick Therapeutics; Regeneron
 
Richard D. Carvajal
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aura Biosciences; Bristol-Myers Squibb/Medarex (Inst); Castle Biosciences; Chimeron Bio; Corvus Pharmaceuticals (Inst); Genzyme; Genzyme; IDEAYA Biosciences (Inst); Immunocore; InxMed; Iovance Biotherapeutics; Merck; Mirati Therapeutics (Inst); Novartis (Inst); Oncosec; Pfizer (Inst); Pierre Fabre; Plexxikon (Inst); PureTech; Regeneron; Regeneron; Rgenix; Roche/Genentech (Inst); Roche/Genentech (Inst); Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Paul K. Paik
Honoraria - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Calithera Biosciences; EMD Serono; GlaxoSmithKline; Takeda; Xencor
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Calithera Biosciences; EMD Serono; GlaxoSmithKline; Takeda; Xencor
Research Funding - Bicara Therapeutics; Boehringer Ingelheim; EMD Serono
 
Alberto Hernando-Calvo
Travel, Accommodations, Expenses - Kyowa Kirin International; Merck Serono
 
Maura L. Gillison
Consulting or Advisory Role - Bayer; Bicara Therapeutics; BioNTech; BioNTech; Bristol-Myers Squibb; Debiopharm Group; EMD Serono; Gilead Sciences; Ipsen; Kura Oncology; Merck; Roche; Shattuck Labs
Research Funding - Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genocea Biosciences (Inst)
 
Siqing Fu
Research Funding - Abbisko (Inst); Anaeropharma (Inst); Arrien Pharmaceuticals (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Hookipa Pharma (Inst); Huya Bioscience International (Inst); IMV (Inst); Innovent Biologics (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Medivir (Inst); Millennium (Inst); NCCN (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NIH/NCI (Inst); Novartis (Inst); NovoCure (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); Taiho Oncology (Inst); Tolero Pharmaceuticals (Inst); Turnstone Bio (Inst)
 
Jennifer J. Wheler
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
Travel, Accommodations, Expenses - Bicara Therapeutics
 
David Bohr
Employment - Bicara Therapeutics; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Amgen; Bicara Therapeutics; Bluebird Bio; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson; Merck
 
Ralf Reiners
Employment - Bicara Therapeutics; Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Bicara Therapeutics
 
Seng-Lai Tan
Employment - Bicara Therapeutics
Stock and Other Ownership Interests - Bicara Therapeutics
Consulting or Advisory Role - Nirogy Therapeutics
 
Sanela Bilic
Consulting or Advisory Role - Bicara Therapeutics
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst)